Memantine hydrochloride is a raw material. It should be prescribed by experienced doctors in the diagnosis and treatment of Alzheimer's dementia and guided by patients. Treatment can only begin when there are caregivers around the patient who regularly supervise the patient's medication. Dementia should be diagnosed in accordance with current diagnostic criteria and guidelines.
Memantine is a medication used to treat moderate-to-severe Alzheimer's disease. It is less preferred than acetylcholinesterase inhibitors such as donepezil. Treatment should only be continued if beneficial effects are seen. It is taken by mouth.
Memantine was approved for medical use in the United States in 2003. It is available as a generic medication. In 2017, it was the 149th most commonly prescribed medication in the United States, with more than four million prescriptions
Memantine is clinically used for the treatment of moderate to severe senile dementia and parkinsonism syndrome. It is a new type of anti-senile dementia drug and can be used for the treatment of moderate to severe senile dementia.
Memantine is used to treat moderate-to-severe Alzheimer's disease, especially for people who are intolerant of or have a contraindication to AChE (acetylcholinesterase) inhibitors.One guideline recommends memantine or an AChE inhibitor be considered in people in the early-to-mid stage of dementia.
Memantine has been associated with a modest improvement; with small positive effects on cognition, mood, behavior, and the ability to perform daily activities in moderate-to-severe Alzheimer's disease. There does not appear to be any benefit in mild disease.
Memantine when added to donepezil in those with moderate-to-severe dementia resulted in "limited improvements" in a 2017 review. The UK National Institute of Clinical Excellence (NICE) issued guidance in 2018 recommending consideration of the combination of memantine with donepezil in those with moderate-to-severe dementia. Effects in autism are unclear. Recent scientific journal reports are showing guarded promise with severe obsessive compulsive disorder.
Við höfum margar hágæða verksmiðjur með djúpri samvinnu, sem getur veitt þér hágæða vörur og samkeppnishæf verð. Og við getum líka veitt afslátt fyrir magninnkaup. Og við erum í samstarfi við mörg fagleg flutningsmiðlunarfyrirtæki, getum afhent vörur þínar á öruggan og sléttan hátt. Afhendingartími er um 3-20 dagar eftir staðfestingu á greiðslu.
Atriði |
Requirements |
Test Results |
appearance |
White or almost white crystalline powder |
White crystalline powder |
Identification |
IR |
Comply |
Related substance |
1-methyladamantane ≤0.3% 1,3,5 -trimethyladamantane ≤0.3% Unknow impuritiy ≤0.1% Total impurity ≤0.5% |
0.13% 0.14% <0.1% <0.4% |
Residue on ignition |
≤0.1% |
0.06% |
Heavy matal |
≤10ppm |
<10ppm |
Loss on drying |
≤0.5% |
0.29% |
Greining |
98.5-101.0% |
99.13% |
Residual Solvents |
Ethyl Acetat: ≤0.5% Ethanol: ≤0.5% |
0.08% 0.12% |
PH |
4.5-5.5 |
5.3 |
Microbial Limits |
Max 5*102 aerobes and fungl per 1g E. Coli: Negative Salmonella: Negative
|
Pass |
Size of distributed particles |
Pass 100μ m |
Conforms |
Niðurstaða |
Meet the requirements |
Memantine is a medication used to treat moderate-to-severe Alzheimer's disease. It is less preferred than acetylcholinesterase inhibitors such as donepezil. Treatment should only be continued if beneficial effects are seen. It is taken by mouth.
Memantine was approved for medical use in the United States in 2003. It is available as a generic medication. In 2017, it was the 149th most commonly prescribed medication in the United States, with more than four million prescriptions
Memantine HCl is the HCl form of Memantine. Memantine is a well- known neuroprotective drug used for the treatment of Alzheimer's disease. It is believed to be the first neuroprotective drug that has achieve clinical approval by US FDA as well as European.
The development of Alzheimer's disease involves the misfolded mutant proteins such as β-amyloid peptide (Aβ, particularly Aβ1−42). These misfolded mutant protein can increase the NMDA response and further cause severe excitotoxicity.
Memantine suppresses this process through acting as the antagonist of the N-methyl-d- aspartate-sensitive glutamate receptor (NMDARs).
Memantine is also under investigation as a potential treatment for other kind of neurodegenerative disorders such as HIV-associated dementia, neuropathic pain, glaucoma, depression, Huntington's disease, ALS and movement disorders, among other.
1. Ertu verksmiðja eða viðskiptafyrirtæki?
Við erum fyrirtæki sem samþættir iðnað og viðskipti og veitum þjónustu á einum stað.OEM gæti verið samþykkt.
2. Gefur þú sýnishorn? Er það ókeypis eða aukalega?
Ókeypis sýnishorn. Greiða þarf vörugjald sýnisins við hliðina á þér.
3. Ertu með einhver vottorð sem tengjast gæðaeftirliti?
ISO 9001:2008 vottun til að tryggja gæði.
4. Hvað ætti ég að veita til að fá tilboð?
Pls upplýstu okkur um vörutegundina sem þú þarft, pöntunarmagn, heimilisfang og sérstakar kröfur. Tilvitnunin verður gerð til viðmiðunar í tíma.
5. Hvers konar greiðslumáta kýst þú? Hvers konar skilmálar eru samþykktir?
Samþykktir afhendingarskilmálar: FOB, CFR, CIF, EXW;
Samþykkt greiðslugjaldmiðill: USD;
Samþykkt greiðslutegund: T/T, Western Union; Paypal, viðskiptatrygging.
Tölt tungumál: Enska.
Vöruflokkar